Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. / Khan, Sabrina; Amin, Faisal Mohammad; Fliedner, Frederikke Petrine; Christensen, Casper Emil; Tolnai, Daniel; Younis, Samaira; Olinger, Anne Christine Rye; Birgens, Henrik; Daldrup-Link, Heike; Kjær, Andreas; Larsson, Henrik Bo Wiberg; Lindberg, Ulrich; Ashina, Messoud.

In: Cephalalgia, Vol. 39, No. 11, 2019, p. 1407-1420.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Khan, S, Amin, FM, Fliedner, FP, Christensen, CE, Tolnai, D, Younis, S, Olinger, ACR, Birgens, H, Daldrup-Link, H, Kjær, A, Larsson, HBW, Lindberg, U & Ashina, M 2019, 'Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging', Cephalalgia, vol. 39, no. 11, pp. 1407-1420. https://doi.org/10.1177/0333102419848122

APA

Khan, S., Amin, F. M., Fliedner, F. P., Christensen, C. E., Tolnai, D., Younis, S., Olinger, A. C. R., Birgens, H., Daldrup-Link, H., Kjær, A., Larsson, H. B. W., Lindberg, U., & Ashina, M. (2019). Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia, 39(11), 1407-1420. https://doi.org/10.1177/0333102419848122

Vancouver

Khan S, Amin FM, Fliedner FP, Christensen CE, Tolnai D, Younis S et al. Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia. 2019;39(11):1407-1420. https://doi.org/10.1177/0333102419848122

Author

Khan, Sabrina ; Amin, Faisal Mohammad ; Fliedner, Frederikke Petrine ; Christensen, Casper Emil ; Tolnai, Daniel ; Younis, Samaira ; Olinger, Anne Christine Rye ; Birgens, Henrik ; Daldrup-Link, Heike ; Kjær, Andreas ; Larsson, Henrik Bo Wiberg ; Lindberg, Ulrich ; Ashina, Messoud. / Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. In: Cephalalgia. 2019 ; Vol. 39, No. 11. pp. 1407-1420.

Bibtex

@article{8ce0f52a98c247d7a2a18e042bda5333,
title = "Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging",
abstract = "Background: Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist. Inflammation pertaining to the wall of cerebral arteries and brain parenchyma has been suggested to play a role in migraine pathophysiology. Objective: We conducted the first experimental human study to investigate macrophage-mediated inflammation as a possible biomarker of migraine. Methods: Using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced 3T magnetic resonance imaging (MRI), we investigated the presence of macrophages in cerebral artery walls and in brain parenchyma of patients with migraine without aura. We used the phosphodiesterase-3-inhibitor cilostazol as an experimental migraine trigger, and investigated both patients who received sumatriptan treatment, and patients who did not. To validate our use of USPIO-enhanced MRI, we included a preclinical mouse model with subcutaneous capsaicin injection in the trigeminal V1 area. The study is registered at ClinicalTrials.gov with the identifier NCT02549898. Results: A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO. Twelve patients treated their attack with 6 mg s.c. sumatriptan, while the remaining 16 patients received no migraine-specific rescue medication. The preclinical model confirmed that USPIO-enhanced MRI detects macrophage-mediated inflammation. In patients, however, migraine attacks were not associated with increased USPIO signal on the pain side of the head compared to the non-pain side. Conclusion: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.",
keywords = "dura mater, ferumoxytol, Headache, inflammation, meningeal nociceptor, USPIO",
author = "Sabrina Khan and Amin, {Faisal Mohammad} and Fliedner, {Frederikke Petrine} and Christensen, {Casper Emil} and Daniel Tolnai and Samaira Younis and Olinger, {Anne Christine Rye} and Henrik Birgens and Heike Daldrup-Link and Andreas Kj{\ae}r and Larsson, {Henrik Bo Wiberg} and Ulrich Lindberg and Messoud Ashina",
year = "2019",
doi = "10.1177/0333102419848122",
language = "English",
volume = "39",
pages = "1407--1420",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "11",

}

RIS

TY - JOUR

T1 - Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging

AU - Khan, Sabrina

AU - Amin, Faisal Mohammad

AU - Fliedner, Frederikke Petrine

AU - Christensen, Casper Emil

AU - Tolnai, Daniel

AU - Younis, Samaira

AU - Olinger, Anne Christine Rye

AU - Birgens, Henrik

AU - Daldrup-Link, Heike

AU - Kjær, Andreas

AU - Larsson, Henrik Bo Wiberg

AU - Lindberg, Ulrich

AU - Ashina, Messoud

PY - 2019

Y1 - 2019

N2 - Background: Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist. Inflammation pertaining to the wall of cerebral arteries and brain parenchyma has been suggested to play a role in migraine pathophysiology. Objective: We conducted the first experimental human study to investigate macrophage-mediated inflammation as a possible biomarker of migraine. Methods: Using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced 3T magnetic resonance imaging (MRI), we investigated the presence of macrophages in cerebral artery walls and in brain parenchyma of patients with migraine without aura. We used the phosphodiesterase-3-inhibitor cilostazol as an experimental migraine trigger, and investigated both patients who received sumatriptan treatment, and patients who did not. To validate our use of USPIO-enhanced MRI, we included a preclinical mouse model with subcutaneous capsaicin injection in the trigeminal V1 area. The study is registered at ClinicalTrials.gov with the identifier NCT02549898. Results: A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO. Twelve patients treated their attack with 6 mg s.c. sumatriptan, while the remaining 16 patients received no migraine-specific rescue medication. The preclinical model confirmed that USPIO-enhanced MRI detects macrophage-mediated inflammation. In patients, however, migraine attacks were not associated with increased USPIO signal on the pain side of the head compared to the non-pain side. Conclusion: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.

AB - Background: Initiating mechanisms of migraine headache remain poorly understood and a biomarker of migraine does not exist. Inflammation pertaining to the wall of cerebral arteries and brain parenchyma has been suggested to play a role in migraine pathophysiology. Objective: We conducted the first experimental human study to investigate macrophage-mediated inflammation as a possible biomarker of migraine. Methods: Using ultrasmall superparamagnetic iron oxide (USPIO)-enhanced 3T magnetic resonance imaging (MRI), we investigated the presence of macrophages in cerebral artery walls and in brain parenchyma of patients with migraine without aura. We used the phosphodiesterase-3-inhibitor cilostazol as an experimental migraine trigger, and investigated both patients who received sumatriptan treatment, and patients who did not. To validate our use of USPIO-enhanced MRI, we included a preclinical mouse model with subcutaneous capsaicin injection in the trigeminal V1 area. The study is registered at ClinicalTrials.gov with the identifier NCT02549898. Results: A total of 28 female patients with migraine without aura underwent a baseline MRI scan, ingested cilostazol, developed a migraine-like attack, and underwent an USPIO-enhanced MRI scan > 24 hours after intravenous administration of USPIO. Twelve patients treated their attack with 6 mg s.c. sumatriptan, while the remaining 16 patients received no migraine-specific rescue medication. The preclinical model confirmed that USPIO-enhanced MRI detects macrophage-mediated inflammation. In patients, however, migraine attacks were not associated with increased USPIO signal on the pain side of the head compared to the non-pain side. Conclusion: Our findings suggest that migraine without aura is not associated with macrophage-mediated inflammation specific to the head pain side.

KW - dura mater

KW - ferumoxytol

KW - Headache

KW - inflammation

KW - meningeal nociceptor

KW - USPIO

U2 - 10.1177/0333102419848122

DO - 10.1177/0333102419848122

M3 - Journal article

C2 - 31104505

AN - SCOPUS:85066874225

VL - 39

SP - 1407

EP - 1420

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 11

ER -

ID: 236663975